The Extent and Nature of Lived Experience Engagement in the Development of Australian Clinical Practice Guidelines, 2014–2025: A Scoping Review
Anneliese Synnot, Naomi MacPherson, Thomas Benning, Bernard Tso, Chuyue Wang, Antonia Arfaras, Brian A. Beh, Vanessa Cullen, Jessica D'Lima, Tony Finneran, David C. Fry, Michelle King, Alexander Meredith, Adrian O'Malley, Joanne Muller, Tari Turner, Samantha P. Chakraborty

TL;DR
This study found that most Australian clinical guidelines involved people with lived experience, but engagement was often limited and lacked detailed reporting.
Contribution
The study reveals that while lived experience engagement is common in Australian guidelines, it is often minimal and lacks comprehensive documentation.
Findings
72% of 150 guidelines included some lived experience engagement, with most involving participants in all stages.
Only 9% used panels or advisory groups, and 5% used online surveys for engagement.
Few guidelines provided details about participants' characteristics or how their input influenced recommendations.
Abstract
To examine the extent and nature of lived experience engagement in Australian clinical practice guideline development. Scoping review of Australian clinical practice guidelines published 1 January 2014–20 March 2025 that reported using a systematic search method and standardised methods for appraising evidence quality and certainty. PubMed, Guidelines International Network library, Google Scholar, the websites of all 25 Australian medical colleges, the Cancer Council, the Heart Foundation, the Stroke Foundation, the National Blood Authority and Caring for Australians and New Zealanders with Kidney Impairment. One hundred and fifty guidelines met the inclusion criteria; 108 (72%) reported some degree of lived experience engagement in their development, of which 98 (91%) described engagement through all development stages and 95 (88%) reported their inclusion as guideline panel…
Genes, proteins, chemicals, diseases, species, mutations and cell lines named across the full text — each resolved to its canonical identifier and authoritative record.
| Characteristic | Number |
|---|---|
| All guidelines | 150 |
| Guideline topic (International Classification of Diseases, eleventh revision category) [ | |
| 01 Certain infectious or parasitic diseases | 4 (3%) |
| 02 Neoplasms | 18 (12%) |
| 03 Diseases of the blood or blood‐forming organs | 1 (1%) |
| 04 Diseases of the immune system | 1 (1%) |
| 05 Endocrine, nutritional or metabolic diseases | 3 (2%) |
| 06 Mental, behavioural or neurodevelopmental disorders | 14 (9%) |
| 07 Sleep–wake disorders | 0 |
| 08 Diseases of the nervous system | 3 (2%) |
| 09 Diseases of the visual system | 0 |
| 10 Diseases of the ear or mastoid process | 0 |
| 11 Diseases of the circulatory system | 6 (4%) |
| 12 Diseases of the respiratory system | 7 (5%) |
| 13 Diseases of the digestive system | 1 (1%) |
| 14 Diseases of the skin | 0 |
| 15 Diseases of the musculoskeletal system or connective tissue | 5 (3%) |
| 16 Diseases of the genitourinary system | 17 (11%) |
| 17 Conditions related to sexual health | 1 (1%) |
| 18 Pregnancy, childbirth or the puerperium | 41 (27%) |
| 19 Certain conditions originating in the perinatal period | 8 (5%) |
| 20 Developmental anomalies | 1 (1%) |
| 21 Symptoms, signs or clinical findings, not elsewhere classified | 1 (1%) |
| 22 Injury, poisoning or certain other consequences of external causes | 1 (1%) |
| 23 External causes of morbidity or mortality | 3 (2%) |
| 24 Factors influencing health status or contact with health services | 14 (9%) |
| Lived experience engagement | |
| Yes | 108 (72%) |
| No | 42 (28%) |
| Received National Health and Medical Research Council approval | |
| Yes | 32 (21%) |
| No | 118 (79%) |
| National Health and Medical Research Council standard | Number |
|---|---|
| All guidelines | 150 |
| People with lived experience participated in guideline development (mandatory) | 108 (72%) |
| Guideline development group included people with lived experience (mandatory) | 95 (63%) |
| Processes to recruit, involve and support people with lived experience described (mandatory) | |
| Recruit | 93 (62%) |
| Involve | 104 (69%) |
| Support | 76 (51%) |
| Searched for evidence of patient preferences and values (desirable) | 22 (15%) |
| Guideline sent to lived experience organisations during public consultation (mandatory) | 52 (35%) |
| Characteristic | Number |
|---|---|
| Guidelines that reported lived experience engagement | 108 |
| Recruitment approach | |
| Open: fixed | 11 (10%) |
| Open: flexible | 2 (2%) |
| Closed: invitation | 11 (10%) |
| Closed: existing group | 70 (65%) |
| Closed: purposive sampling | 0 |
| Not reported | 23 (21%) |
| Recruitment source [ | |
| Lived experience groups | 82 (76%) |
| Patient records from health care providers | 1 (1%) |
| People with lived experience | 0 |
| Contacts of researcher or guideline developer | 10 (9%) |
| Not reported | 15 (14%) |
| Number of people with lived experience | |
| 1 | 61 (56%) |
| 2 | 14 (13%) |
| 3–10 | 19 (18%) |
| More than 10 | 10 (9%) |
| Not reported | 4 (4%) |
| Type of people with lived experience | |
| Person with lived experience/patient | 30 (28%) |
| Family member | 16 (15%) |
| Advocate | 7 (6%) |
| Organisational representative | 14 (13%) |
| Not reported | 69 (64%) |
| PROGRESS‐Plus characteristics [ | |
| Place of residence | 5 (5%) |
| Race/culture/ethnicity/language | 11 (10%) |
| Occupation | 1 (1%) |
| Gender/sex | 1 (1%) |
| Religion | 0 |
| Education (limited) | 1 (1%) |
| Socio‐economic status | 1 (1%) |
| Social capital | 0 |
| Age | 2 (2%) |
| Sexual orientation | 0 |
| Disability | 2 (2%) |
| Not reported | 94 (87%) |
| Characteristic | Number |
|---|---|
| Guidelines that reported lived experience engagement | 108 |
| Co‐design lived experience engagement | |
| Yes | 11 (10%) |
| No | 97 (90%) |
| Guideline stages | |
| Priority setting and topic selection | 7 (6%) |
| Question generation | 5 (5%) |
| Evidence synthesis | 3 (3%) |
| Developing recommendations | 4 (4%) |
| Public consultation | 1 (1%) |
| Dissemination and implementation | 2 (2%) |
| Evaluation and use | 0 (0%) |
| Throughout | 98 (91%) |
| Not reported | 3 (3%) |
| Methods of engagement | |
| Guideline panel member | 95 (88%) |
| Interviews | 2 (2%) |
| Focus groups | 3 (3%) |
| Workshops/seminars/group consensus | 1 (1%) |
| Delphi/individual consensus study | 1 (1%) |
| Lived experience panel/advisory group | 10 (9%) |
| Online survey | 5 (5%) |
| Other | 2 (2%) |
| Not reported | 5 (5%) |
| Multiple methods of engagement | |
| Yes | 17 (16%) |
| No | 91 (84%) |
| Mode of engagement | |
| Online | 27 (25%) |
| Face‐to‐face | 27 (25%) |
| Mixed | 14 (13%) |
| Can't tell | 46 (43%) |
| Assigned tasks/roles | |
| Chair of committee or group | 6 (6%) |
| Governance/approval role | 64 (60%) |
| Decide, advise or vote on recommendations/guideline content | 97 (90%) |
| Write guideline content (e.g., lay version) | 7 (7%) |
| Contribute views, opinions and experiences | 20 (19%) |
| Feedback | 0 |
| Other | 2 (2%) |
| Not reported | 3 (3%) |
| Support provided [ | |
| Practical support | 49 (45%) |
| Informal support | 17 (16%) |
| Emotional support | 1 (1%) |
| Remuneration | 60 (56%) |
| Co‐learning and training | 17 (16%) |
| Provide re‐assessment and feedback | 0 |
| Manage group dynamics | 41 (38%) |
| Not reported | 32 (30%) |
| Support provided to guideline developers | |
| Training | 2 (2%) |
| Funding | 2 (2%) |
| Designated staff | 6 (6%) |
| Other | 1 (1%) |
| Not reported | 99 (92%) |
| Level of engagement | |
| Inform | 0 |
| Consult | 1 (1%) |
| Involve | 9 (8%) |
| Collaborate | 99 (92%) |
| Empower | 1 (1%) |
| Unable to determine | 3 (3%) |
| Evaluation of lived experience engagement | |
| Yes | 5 (5%) |
| Guideline title | Lived experience engagement methods |
|---|---|
| National guideline for the assessment and diagnosis of autism in Australia [ | Guideline development group co‐chair had autism; three further lived experience guideline development group members (two people with autism, one parent). Two organisational representatives sat on the reference group, the role of which was to support community consultation. Community consultation consisted of an online survey (805 responses) and 9 focus groups (68 attenders) to learn about the community experiences, views and preferences regarding the assessment and diagnosis of autism. |
| Australian guideline and calculator for assessing and managing cardiovascular disease risk [ | Lived experience advisory group (10 people), comprising people with lived experience and family members, including Indigenous representatives, provided feedback on recommendations and guideline content. The chair of the consumer advisory group also sat on the expert steering group and the expert subgroup. |
| Australian and New Zealand Living Clinical Guidelines for Stroke Management [ | A 26‐member lived experience panel, comprising stroke survivors and family members, contributed chiefly by email (commenting on recommendations and writing plain language versions of recommendations). For each topic being updated, two to four members join the content development working group to update recommendations. The whole panel was then invited to review and comment on the draft changes. |
| Clinical practice guidelines for hepatocellular carcinoma surveillance for people at high risk in Australia [ | Expert advisory group (equivalent to guideline development group) included three lived experience advocates, who, together with one further person with lived experience, were also members of a community reference group, which reviewed the guidelines from a patient perspective. |
| Recommendations for culturally safe and clinical kidney care in First Nations Australians [ | Conducted community consultations (yarning kidneys) in 16 communities across Australia (number of participants not reported) to assess community needs and preferences relevant to the proposed guidelines. Three Indigenous people with chronic kidney disease were members of the working group. |
|
Australian Pregnancy Care Guidelines [ Australian Postnatal Care Guidelines [ | Online surveys of people with lived experience to identify priority topics for the guideline, a 16‐member lived experience panel to review draft recommendations, 4 co‐chairs and deputy co‐chairs were members of the guidelines leadership group, 2 co‐chairs/deputy co‐chairs each sat on the pregnancy and postnatal panels. |
| Australian Physical Activity Clinical Practice Guideline for people with moderate to severe traumatic brain injury [ | Focus groups and interviews with people with lived experience and family members (number of participants not reported) to assess views about the guideline topic. One person with lived experience included in the research programme team and guidelines leadership group; eight people with lived experience and family members included in the guideline development group. |
Peer Reviews
No public reviews on file for this paper yet. If you reviewed it on a platform where reviews are public (OpenReview, ICLR, NeurIPS, ICML), you can paste yours below so the community can read it here.
Videos
No videos yet. Explain this paper in a talk, walkthrough, or lecture? Add one.
Taxonomy
TopicsMental Health and Patient Involvement · Clinical practice guidelines implementation · Health Policy Implementation Science
Introduction
1
Clinical practice guidelines are recommendations for clinicians making health care decisions. Major guideline bodies, such as the World Health Organization, the United States Institute of Medicine and the National Health and Medical Research Council (NHMRC), recommend that the guideline development process include people with lived experience of the topic or condition covered by the guidelines, members of their families or their representatives [1, 2, 3]. Their engagement can take many forms, such as membership of guideline development groups and participation in prioritisation surveys, workshops and interviews [4, 5, 6], at any stage of the guideline development process [7], leading to more person‐centred guidelines [8, 9].
The extent of and expectations regarding lived experience engagement in health research have shifted considerably since the early 2000s [10, 11, 12]. Areas that have attracted greater attention include sharing power with people with lived experience [13], their meaningful and effective engagement [14], and increasing equity, in part by reducing barriers to participation for people from groups who are less heard [15]. Nevertheless, shifts in the guideline development community have been slow; recent studies reported that only 8% of United States guideline development organisations (2017) [16] and 11% of Latin American guidelines (2022) [17] included people with lived experience of the topic in their guideline development groups.
In Australia, guideline development is decentralised, undertaken by government health departments, medical colleges, disease‐specific charity groups and research institutions [18]. The NHMRC produces a small number of guidelines and has a formal approval process for externally produced guidelines developed using NHMRC methods [3]. According to NHMRC standards, guideline developers must involve people with lived experience in guideline development groups and throughout the development process, and report how they were recruited, engaged and supported [3, 19]. A 2014 analysis of Australian guidelines, undertaken prior to the publication of the first (2016) NHMRC guideline standards, found that 14% reported lived experience engagement in their development [18]. Lived experience engagement in Australian guideline development has not since been investigated.
We therefore examined the extent and nature of lived experience engagement in Australian clinical practice guideline development.
Methods
2
We followed JBI guidance for the conduct of scoping reviews [20, 21] and report our scoping review according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analysis extension for Scoping Reviews (PRISMA‐ScR) [22]. We did not publish the review protocol.
Participants
2.1
We defined ‘people with lived experience’ as people with lived experience of health conditions, patients and potential patients, informal caregivers, people who use health care services, and community members and their representatives, including organisational representatives.
Core Concepts
2.2
We defined ‘lived experience engagement’ as active involvement in a bi‐directional relationship that results in informed decision‐making at any stage of the guideline development process [23]. We used an operational definition of the engagement of one or more people with lived experience at any stage of the process, with the exception of the public consultation stage and formal searches for information about patients' preferences, values and experiences to inform recommendation development. We defined the extent of lived experience engagement as its prevalence, and its nature as its key features, most frequently recruitment, guideline stages during which their engagement was reported, methods of engagement and training and support provided.
Context
2.3
We included Australian guidelines published during 1 January 2014–20 March 2025. This period was selected because of the growth in lived experience engagement expectations, practice and methods during this period, and our desire to examine current practice. We used the US Institute of Medicine definition of guidelines: ‘statements that include recommendations, intended to optimise patient care, that are informed by a systematic review of evidence and an assessment of the benefits and harms of alternative care options’ [2]. We included guidelines that clearly described a systematic search (e.g., questions framed using population, intervention, comparison and outcomes, databases or search strings) and methods for appraising the quality and certainty of the evidence (e.g., Grading of Recommendations Assessment, Development, and Evaluation [GRADE] [24]). We included guidelines designed to guide clinical practice related to any population group or health condition, apart from those pertaining to public health and allied health. We selected guidelines with a national scope, including those that applied to both Australia and New Zealand.
Document Sources
2.4
We included guideline documents and any related reports, such as technical reports or journal articles, that described guideline development methods.
Search Strategy
2.5
With the assistance of an information specialist, we searched the following databases and document repositories on 20 March 2025:
- PubMed (search string: Australia*[ti] AND (guideline*[ti] OR guideline[pt]));
- Guidelines International Network Library (https://guidelines.ebmportal.com) (filter: Australia).
We also searched the following databases and sources: ECRI Guidelines Trust (https://guidelines.ecri.org); MAGICapp (https://app.magicapp.org); Google ‘Australian guideline’ and Google Scholar ‘Australian guideline’ (first five result pages each checked); and the websites of all 25 Australian medical colleges, the Cancer Council (https://www.cancer.org.au), the Heart Foundation (https://www.heartfoundation.org.au), the Stroke Foundation (https://strokefoundation.org.au), the National Blood Authority (https://www.blood.gov.au) and Caring for Australians and New Zealanders with Kidney Impairment (https://www.cariguidelines.org). Search results were collated and duplicates removed in EndNote 20; the documents were screened in Covidence.
Selection Process
2.6
Two reviewers (from authors NM, TB and CW) independently screened the titles and abstracts of items identified by the searches; disagreements were resolved by consensus or discussion with a third reviewer (one of the authors AS and SC). One reviewer (from NM, TB and CW) independently screened the full text of documents selected by screening; a second reviewer (SC) checked about 10% of these documents, and merged any guideline chapters as single guideline documents, as appropriate.
Data Charting Items and Process
2.7
Two authors (AS and TT) devised and piloted a standardised template in Excel (Microsoft) for data charting. We drew upon existing frameworks [25, 26] to inform how we categorised data items (template: Table S1). Briefly, we recorded the guideline topic, year of publication, whether the guideline met any of the NHMRC standards related to people with lived experience of the topic, and whether the guideline was developed with any lived experience engagement. We used the 2022 NHMRC standards [27] for data charting (the 2025 standards [3] had not yet been published). For guidelines that reported lived experience engagement, we extracted information about their approach, such as the number and characteristics of the people engaged, the guideline stages in which they were involved, the methods of engagement and support provided to people with lived experience and guideline developers. We used PROGRESS‐Plus health equity characteristics to chart the diversity characteristics of the people with lived experience who were engaged in the guidelines [28, 29]. One reviewer (from TB, NM, BT, CW and AS) conducted data charting; queries were discussed with a senior author (AS or SC). A second reviewer (from AS, SC, BT and CW) checked all data charting, looked for errors and inconsistencies and directly amended the data charting spreadsheet.
Synthesis
2.8
To determine the extent of lived experience engagement in Australian guideline development, we calculated the proportion of guidelines in which one or more people with lived experience of the topic had been involved in their development. To determine the nature of lived experience engagement in Australian guidelines, we considered the key features of their engagement. We provide detailed accounts of a selection of guidelines with more extensive lived experience engagement.
Lived Experience Engagement in Our Scoping Review
2.9
We presented an early version of our review findings to an online meeting of the Australian Living Evidence Collaboration (https://livingevidence.org.au) 10‐member lived experience advisory group in September 2024. Feedback from the group led to the addition of further data charting items, refined how the results were presented, identified key messages and highlighted points that were included in the discussion. Group members were subsequently invited to comment on the manuscript and discuss changes with the authors at an online meeting.
Results
3
We identified 1367 potentially relevant records related to 1278 documents (some guidelines were reported in several publications or were published as chapters that we merged into single documents) in the searched databases, repositories and other sources. After removing 103 duplicates, we screened the titles and abstracts of 1175 unique items; we subsequently reviewed the full text of 485 documents deemed potentially relevant after screening titles and abstracts. After excluding 335 documents deemed to be ineligible for our review, we included 150 guidelines in our scoping review (Figure S1, Table S2).
Characteristics of Included Guidelines
3.1
The most frequent guideline topics were pregnancy, childbirth or the puerperium (41 guidelines), neoplasms (18 guidelines), diseases of the genitourinary system (17 guidelines), mental, behavioural or neurodevelopmental disorders (14 guidelines) and factors influencing health status or contact with health services (14 guidelines). A total of 108 guidelines (72%) described lived experience engagement in their development, and 42 guidelines (28%) did not; 32 guidelines had received NHMRC approval (Table 1).
Ninety‐five guidelines (63%) reported that people with lived experience were included in the guideline development group, consistent with the NHMRC guideline development standards [27]; recruitment processes were described in 93 guidelines (62%), involvement processes in 104 (69%) and support processes (e.g., remuneration and practical support) in 76 (51%). Twenty‐two guidelines (15%) reported searches for information about patient preferences and values; 52 (35%) reported sending the guideline to patient organisations during public consultations (Table 2).
Nature of Lived Experience Engagement in Guidelines
3.2
Of the 108 guidelines that reported lived experience engagement, 81 reported using closed recruitment approaches (seeking people from existing groups, 70 [65%]; by personal invitation, 11 [10%]). People were recruited from lived experience groups for 82 guidelines (76%) or were known contacts of the guideline developers for 10 (9%) (Table 3).
One person with lived experience was reported to have participated in the development process for 61 guidelines (56%), two people for 14 guidelines (13%), 3–10 people for 19 guidelines (18%) and more than 10 people for 10 guidelines (9%). The type of lived experience was not reported by 69 guidelines (64%); in 30 cases, they were people with direct lived experience (28%), in 16 cases family members (15%), in 14 cases organisational representatives (13%) and in 7 cases patient advocates (6%). Ninety‐four guidelines (88%) did not report the personal characteristics of people with lived experience; the characteristics most frequently reported were race/culture/ethnicity/language (11 guidelines, 10%) and place of residence (5 guidelines, 5%) (Table 3).
Eleven guidelines (10%) reported co‐designing lived experience engagement with people with lived experience. Ninety‐eight (91%) reported involving them throughout guideline development; when engagement was limited to specific stages, it was most frequently priority setting and topic selection (7 guidelines, 6%), question generation (5, 5%) or developing recommendations (4, 4%); guideline evaluation and use was the only stage in which people with lived experience were never involved. The method of engagement was as guideline panel members for 95 guidelines (88%), on lived experience panels or advisory groups for 10 (9%), in online surveys for 5 (5%) and in focus groups for 3 guidelines (3%); 17 guidelines (16%) reported multiple methods. The mode of engagement was reported as online in 27 cases (25%), face‐to‐face in 27 (25%) and mixed in 14 (13%); the mode was not reported for 46 guidelines (43%). For 97 guidelines (90%), people with lived experience were asked to decide, advise or vote on recommendations or guideline content, for 64 guidelines (60%) they had governance or approval roles, and for 20 guidelines (19%) they were invited to contribute their views, opinions and experiences. Seven guidelines reported that people with lived experience wrote guideline content (e.g., lay versions); six guidelines reported that they had chaired committees or groups (Table 4).
The most frequently reported support for people with lived experience was remuneration (60 of 108 guidelines, 56%), practical support (e.g., plain language meeting papers; 49 guidelines, 45%), management of group dynamics (e.g., chairperson ensured they could actively contribute; 41 guidelines, 38%), informal support (e.g., help with technical queries; 17 guidelines, 16%) and co‐learning and training (e.g., initial orientation and training session; 17 guidelines, 16%). Support provided for guideline developers was not reported in 99 of 108 guidelines (92%); six guidelines reported designated staff for supporting lived experience engagement, two reported training for guideline developers and two reported support funding. The level of engagement according to International Association for Public Participation Australasia definitions [26] was ‘collaborate’ (‘to partner with the public in each aspect of the decision’; 99 of 108 guidelines, 92%), ‘involve’ (‘to work directly with the public throughout the process to ensure that public concerns and aspirations are consistently understood and considered’; nine guidelines), ‘consult’ (‘to obtain public feedback on analysis, alternatives and/or decisions’; one guideline) or ‘empower’ (‘to place the final decision in the hands of the public’; one guideline). Five guidelines reported evaluating lived experience engagement (Table 4).
Examples of More Extensive Lived Experience Engagement
3.3
Extensive lived experience engagement was reported for the development of eight guidelines. For the autism assessment and diagnosis guideline [32], people with lived experience were guideline development group members (including one co‐chair), and the developers conducted a large community consultation using online surveys and focus groups. The national stroke living guidelines [33] are developed with a large lived experience panel that reviews and comments on guideline content, two to four members of which join the content development working group when new topics are updated. The guideline for culturally safe and clinical kidney care for First Nations Australians [34] was developed after ‘yarning kidneys’ community consultations across Australia, and three Indigenous people were included as working group members (Table 5).
Discussion
4
Our scoping review of the extent and nature of lived experience engagement in Australian clinical guideline development included 150 guidelines published during 2014–2025. We found that 108 guidelines (72%) reported involving people with lived experience in their development, of which 61 (56%) reported the participation of one person with lived experience and 14 (13%) of two people with lived experience. Ninety‐eight guidelines (91%) reported lived experience engagement throughout guideline development, primarily as guideline panel members. Very little information about the characteristics of the participating people with lived experience was reported.
The prevalence of lived experience engagement in Australian guideline development during 2014–2025 was much higher than in 2014 (14% [18]); it was also higher than more recently reported for the United States (8% [17]) and Latin America (11% [16]). Lived experience engagement in Australian guideline development may be growing, but it typically consists of one to two people as members of guideline development groups. If only one layperson sits on a group primarily comprised of clinicians, power imbalances can make the experience less than ideal, both for them and for guideline developers [40, 41]. The instances of more extensive engagement we identified are more encouraging. While not appropriate for all guidelines, they provide developers with examples of feasible, effective methods of lived experience engagement.
Nevertheless, it is likely that lived experience engagement in Australian guideline development will continue to be chiefly in the form of development group members. The NHMRC has recently revised its guideline development standards [3]; they now require ‘at least two’ people with lived experience in the guideline development group (previously: one) [3], which should strengthen lived experience engagement. However, based on our professional and personal experience, we believe at least four people should be included, and that consideration be given to their diversity (cultural, gender, age and health literacy) and to the fact that they may require extra support to contribute effectively.
Guideline developers could use our findings to assess their lived experience engagement activities and to find ideas for improving them. The limited reporting of lived experience engagement in Australian guideline development may reflect the limited emphasis on this aspect in widely used reporting tools, such as AGREE II [42]. If amended, these tools could encourage more transparent and comprehensive reporting. A qualitative study of the experiences and perspectives of Australian guideline developers and people with lived experience in guideline development would be useful.
Limitations
4.1
Firstly, searching for Australian guidelines is difficult because of the diversity of guideline producers and the absence of a single guideline publishing platform. We believe we identified the vast majority of guidelines, but our sample may be incomplete. Secondly, we did not contact guideline developers to obtain missing information; if we had done so, it which could have yielded a more complete picture, potentially altering some findings. For example, some aspects of lived experience engagement, including remuneration and other support, may not always be reported. Conversely, as we selected guidelines that adhered to our minimum threshold for guideline quality, they may have been more likely to have engaged people with lived experience in their development than other Australian guidelines. Thirdly, although we used the widely accepted US Institute of Medicine definition of ‘guideline’ [2], identifying and categorising unique guidelines is difficult, as they differ in their clinical scope and breadth of topics covered, and sub‐topics or chapters are often published as stand‐alone documents. We grouped guidelines according to the International Classification of Diseases chapters, but this categorisation may not accurately reflect the number of unique guidelines in Australia. Fourthly, we did not assess the overall quality of the included guidelines using a tool such as AGREE II [42], as would be required for assessing the relationship between guideline quality and reported lived experience engagement, but this was not our study aim. Finally, we did not distinguish between laypeople and health professionals as people with lived experience; this information was not usually reported. Including health professionals with lived experience of the topic of the guideline, as people with lived experience can be problematic, particularly if they are the only participating person with lived experience, as they cannot avoid wearing two hats [43].
Conclusion
5
Most Australian clinical practice guidelines published during 2014–2025 reported lived experience engagement in the guideline development process, in contrast to a 2014 report. However, extensive lived experience engagement was not reported for the vast majority of guidelines. The engagement of people with lived experience in guideline development needs to be improved to ensure that their values, views and preferences are reflected.
Author Contributions
Anneliese Synnot: conceptualisation, formal analysis, investigation, methodology, supervision, project administration, validation, writing (original draft), writing (review and editing). Naomi MacPherson: investigation, methodology, validation, writing (review and editing). Thomas Benning: Investigation, Methodology, Validation, Writing (review and editing). Bernard Tso: investigation, methodology, validation, writing (review and editing). Chuyue Wang: investigation, methodology, validation, writing (review and editing). Toni Arfaras: methodology, writing (review and editing). Brian Beh: methodology, writing (review and editing). Vanessa Cullen: methodology, writing (review and editing). Jessica D'Lima: methodology, writing (review and editing). Tony Finneran: methodology, writing (review and editing). David Fry: methodology, writing (review and editing). Michelle King: methodology, writing (review and editing). Alexander Meredith: methodology, writing (review and editing). Jo Muller: methodology, writing (review and editing). Adrian O'Malley: methodology, writing (review and editing). Tari Turner: conceptualisation, methodology, writing (review and editing). Samantha Chakraborty: investigation, methodology, validation, formal analysis, supervision, writing (review and editing).
Funding
The authors have nothing to report.
Disclosure
Not commissioned; externally peer reviewed.
Conflicts of Interest
The authors declare no conflicts of interest.
Supporting information
Data S1: mja270132‐sup‐0001‐supinfo.pdf.
The reference list from the paper itself. Each links out to its DOI / PubMed record.
- 1World Health Organization , WHO Handbook for Guideline Development, 2nd ed., (World Health Organization, 2014), accessed September 2025, https://www.who.int/publications/i/item/9789241548960.
- 2Institute of Medicine (US) , Clinical Practice Guidelines We Can Trust (National Academies Press, 2011), accessed September 2025, https://www.ncbi.nlm.nih.gov/books/NBK 209539.
- 3National Health and Medical Research Council , “Procedures and Requirements for Meeting NHMRC Standards for Clinical Practice Guidelines,” Version 2.0, accessed September 2025, https://www.nhmrc.gov.au/about‐us/publications/procedures‐and‐requirements‐meeting‐nhmrc‐standards‐clinical‐practice‐guidelines.
- 4F. Légaré , A. Boivin , T. van der Weijden , et al., “Patient and Public Involvement in Clinical Practice Guidelines: A Knowledge Synthesis of Existing Programs,” Medical Decision Making 31 (2011): E 45–E 74.21959267 10.1177/0272989 X 11424401 · doi ↗ · pubmed ↗
- 5A. Synnot , S. Hill , A. Jauré , et al., “Broadening the Diversity of Consumers Engaged in Guidelines: A Scoping Review,” BMJ Open 12 (2022): e 058326.10.1136/bmjopen-2021-058326 PMC 920443035710237 · doi ↗ · pubmed ↗
- 6E. A. Bryant , A. M. Scott , H. Greenwood , and R. Thomas , “Patient and Public Involvement in the Development of Clinical Practice Guidelines: A Scoping Review,” BMJ Open 12 (2022): e 055428.10.1136/bmjopen-2021-055428 PMC 952858736171042 · doi ↗ · pubmed ↗
- 7J. Petkovic , O. Magwood , T. W. Concannon , et al., “The GIN–Mc Master Guideline Development Checklist Extension for Engagement,” Journal of Clinical Epidemiology 181 (2025): 111727.39971165 10.1016/j.jclinepi.2025.111727 · doi ↗ · pubmed ↗
- 8M. J. Armstrong , C. D. Mullins , G. S. Gronseth , and A. R. Gagliardi , “Impact of Patient Involvement on Clinical Practice Guideline Development: A Parallel Group Study,” Implementation Science 13 (2018): 55.29661195 10.1186/s 13012-018-0745-6PMC 5902835 · doi ↗ · pubmed ↗
